Peptide microarray of pediatric acute myeloid leukemia is related to relapse and reveals involvement of DNA damage response and repair

Oncotarget
Hasan MahmudEveline S J M de Bont

Abstract

The majority of acute myeloid leukemia (AML) patients suffer from relapse and the exact etiology of AML remains unclear. The aim of this study was to gain comprehensive insights into the activity of signaling pathways in AML. In this study, using a high-throughput PepChip™ Kinomics microarray system, pediatric AML samples were analyzed to gain insights of active signal transduction pathway. Unsupervised hierarchical cluster analysis separated the AML blast profiles into two clusters. These two clusters were independent of patient characteristics, whereas the cumulative incidence of relapse (CIR) was significantly higher in the patients belonging to cluster-2. In addition, cluster-2 samples showed to be significantly less sensitive to various chemotherapeutic drugs. The activated peptides in cluster-1 and cluster-2 reflected the activity of cell cycle regulation, cell proliferation, cell differentiation, apoptosis, PI3K/AKT, MAPK, metabolism regulation, transcription factors and GPCRs signaling pathways. The difference between two clusters might be explained by the higher cell cycle arrest response in cluster-1 patients and higher DNA repair mechanism in cluster-2 patients. In conclusion, our study identifies different signaling...Continue Reading

References

Jun 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·F MavilioC Peschle
Jan 13, 2001·Oncogene·Q WangM I Greene
Apr 30, 2003·Nature Cell Biology·Craig StevensNicholas B La Thangue
Oct 9, 2008·Blood·Steven M KornblauGordon B Mills
Dec 24, 2008·Nature Reviews. Cancer·Jianming ZhangNathanael S Gray
May 12, 2009·BMC Medical Genomics·Tatiana NikolskayaValery I Shestopalov
Jul 2, 2009·Cancer Research·Arend H SikkemaEveline S J M de Bont
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven M KornblauKevin R Coombes
Dec 8, 2010·Leukemia & Lymphoma·Arja Ter ElstEveline S J M de Bont
Jun 7, 2011·Critical Reviews in Oncology/hematology·Arend H SikkemaEveline S J M de Bont
Aug 11, 2012·Blood·Ursula CreutzigUNKNOWN AML Committee of the International BFM Study Group
Aug 17, 2012·Cell Cycle·Srikanth Talluri, Frederick A Dick
Dec 18, 2012·Blood·Stephen J Forman, Jacob M Rowe
May 9, 2013·Seminars in Cancer Biology·Chung-Jung Tsai, Ruth Nussinov
May 30, 2013·American Society of Clinical Oncology Educational Book·Catherine C Smith, Neil P Shah
Jan 15, 2014·Current Opinion in Hematology·Shira N DinnerJessica K Altman
Jun 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Massimo NegriniAntonino Neri
Dec 9, 2014·Biochimica Et Biophysica Acta·Isabella FaraoniFrancesco Lo-Coco
May 7, 2015·Molecular Cancer Research : MCR·K R KampenE S J M De Bont
Dec 28, 2018·Blood Advances·Andrew Hantel, Richard A Larson
Jan 29, 2019·Trends in Molecular Medicine·Amit J Sabnis, Trever G Bivona

❮ Previous
Next ❯

Methods Mentioned

BETA
peptide microarray array
peptide array
peptide
chip

Software Mentioned

ScanAlyze
MetaCoreTM
Metacore
Metacore GenoGo
Metacore GeneGo
Qlucore Qmics Explorer
MetaCore TM
SPSS ( Statistical Package for the Social Sciences
GeneGO

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.